Translating Discoveries into Therapies
Despite aggressive treatment, many children with medulloblastoma experience relapse or have long-term side effects. Current therapies are not tailored to the molecular features of individual tumors. There is a critical need for targeted, less toxic treatment strategies. We are translating our molecular insights into novel therapeutic approaches for medulloblastoma.
Our Discoveries
Our translational research is focused on developing therapies that target the unique vulnerabilities of medulloblastoma. Our work has led to the following therapeutic advances:
Pioneering improved experimental models of pediatric brain tumors
Our lab pioneered the use of human pluripotent stem cell (hPSC) derivatives to model pediatric brain tumor progression.
Dual mTORC1/mTORC2 inhibitors show efficacy in preclinical models
Our research identified the transcription factor OTX2 as a key driver of tumor growth.
Combining MEK and JAK/STAT3 inhibitors to overcome resistance in SHH medulloblastoma
We found that targeting the MEK pathway with the inhibitors selumetinib or trametinib slows tumor growth in Sonic Hedgehog (SHH) medulloblastoma models.
Join us in transforming the future of pediatric brain cancer care.
